IPP Bureau
AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
By IPP Bureau - September 24, 2025
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
By IPP Bureau - September 24, 2025
The facility has been classified as Voluntary Action Indicated
Merck & Siemens join forces to accelerate AI drug discovery and development
By IPP Bureau - September 24, 2025
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Corning, SGD Pharma opens Rs 500 crore glass tubing facility in Telangana
By IPP Bureau - September 24, 2025
Corning and SGD Pharma formed JV in June 2023 to expand pharmaceutical manufacturing in India
Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
By IPP Bureau - September 24, 2025
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas
By IPP Bureau - September 24, 2025
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine
By IPP Bureau - September 24, 2025
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Poly Medicure acquires Italy’s Citieffe Group for Rs. 324 Cr
By IPP Bureau - September 24, 2025
Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad
By IPP Bureau - September 24, 2025
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy
By IPP Bureau - September 24, 2025
Agency initiates safety label change and notifies physicians of possible link
Teva unveils promising SOLARIS resultsfor Olanzapine LAI
By IPP Bureau - September 23, 2025
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Akums demonstrates clinical versatility of Lacosamide in epilepsy care
By IPP Bureau - September 23, 2025
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Roche’s subcutaneous lunsumio receives CHMP backing for R/R follicular lymphoma
By IPP Bureau - September 23, 2025
Moderna delivers Canada’s first locally manufactured mRNA vaccines
By IPP Bureau - September 23, 2025
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
